Misotac

Misotac is a pharmaceutical product containing misoprostol, a synthetic analogue of prostaglandin E1 (PGE1). Produced by Sigma Pharmaceutical Industries in Egypt, it is typically formulated as 200 microgram tablets for oral, sublingual, vaginal, or rectal administration. The drug is extensively utilized in obstetrics and gynecology for its potent uterotonic and cervical-ripening properties. Its primary mechanism of action involves acting as an agonist at prostaglandin receptors in the uterine myometrium, leading to increased strength and frequency of contractions, and in the cervix, where it promotes collagen degradation and softening. Clinically, Misotac is employed for medical abortion, induction of labor, the prevention and treatment of postpartum hemorrhage (particularly during cesarean sections), and cervical priming prior to diagnostic or surgical procedures. It is also being investigated for reducing blood loss in surgeries such as myomectomies and treating abnormal uterine bleeding associated with isthmocele. Misotac's stability at room temperature and ease of administration make it a critical therapeutic option in various clinical settings.

Brand names

Misotac

Other names

misoprostol